Human Epidermal Growth Factor Receptor-2 positive metastatic salivary duct carcinoma with remarkable response to targeted therapy: a case report and therapeutic implications.
Clara Rodrigo Juan, Carla Climent Vicente, Francisco Xavier Avilés Jurado et al.
✦ AI-curated · Sources linked
Case in brief
A middle-aged man with metastatic salivary duct carcinoma (SDC) had a HER2-positive tumour. Treatment with trastuzumab and docetaxel was followed by a near-complete pathological and radiological response, which enabled surgical resection for locoregional control. The report describes an encouraging response to HER2-targeted systemic therapy in metastatic SDC, followed by surgery as part of management.
What made this case unusual
The near-complete pathological and radiological response to trastuzumab plus docetaxel made resection for locoregional control possible despite metastatic disease.
Diagnostic / clinical pearl
HER2 status can inform systemic treatment options in salivary duct carcinoma; in this case, response to trastuzumab and docetaxel enabled subsequent locoregional surgery.